[18F]Florbetazine用于心脏淀粉样变性无创PET检测的临床前与初步临床评价
本研究评估阿尔茨海默病淀粉样蛋白示踪剂[18F]Florbetazine用于心脏淀粉样变性(CA)检测的可行性。体外放射自显影证实其与AL和ATTR沉积物特异性结合(Kd=20.85 nM和54.10 nM),大鼠微PET/CT显示快速心肌和肾脏摄取后有效清除,健康志愿者注射后40分钟背景心肌和肾脏活性极低,1例活检证实的AL淀粉样变性患者延迟相(60-70分钟)PET/CT显示心肌和肾脏强烈摄取并与肾活检结果一致。结论认为该示踪剂亲和力高、药代动力学良好,值得在更大规模系统设计的临床研究中进一步验证。
要点
- [18F]Florbetazine与AL和ATTR心脏淀粉样沉积物均特异性结合,亲和力高。
- 健康志愿者注射后40分钟背景心肌和肾脏活性极低,利于图像判读。
- 1例AL淀粉样变性患者延迟相PET/CT心肌和肾脏强烈摄取,与肾活检一致。
核心结论
- [18F]Florbetazine以高亲和力结合心脏淀粉样蛋白并显示良好药代动力学,值得在更大规模系统设计的临床研究中进一步验证。
研究设计与样本
- 临床前研究:在人心肌切片上进行体外放射自显影评估[18F]Florbetazine与AL和ATTR沉积物的特异性结合和亲和力。
- 临床前研究:在健康Sprague Dawley(SD)大鼠中通过动态micro-PET/CT成像表征药代动力学和生物分布。
- 初步临床研究:在2名健康志愿者中行全身PET/CT成像以评估正常器官本底,在1例活检证实的AL淀粉样变性患者中初步探索诊断可行性。
主要发现
- 放射自显影证实[18F]Florbetazine与AL和ATTR沉积物均特异性结合,结合亲和力高(Kd分别为20.85 nM和54.10 nM)。
- 大鼠中[18F]Florbetazine显示快速心肌和肾脏摄取,随后从正常组织有效清除。
- 健康志愿者注射后40分钟背景心肌和肾脏活性极低。
- AL淀粉样变性患者延迟相PET/CT成像(60-70分钟)显示心肌和肾脏强烈摄取,与肾活检结果一致。
关键数值与推荐
- 体外放射自显影测得[18F]Florbetazine与AL沉积物结合Kd=20.85 nM,与ATTR沉积物结合Kd=54.10 nM。
- 健康志愿者注射后40分钟背景心肌和肾脏活性极低。
- AL淀粉样变性患者延迟相PET/CT成像时间为注射后60-70分钟。
临床怎么用
- 现有数据支持[18F]Florbetazine作为CA无创PET检测的候选示踪剂,但尚处初步阶段,需更大规模系统设计的临床研究验证后方可用于常规临床。
局限性
- 临床评估仅纳入2名健康志愿者和1例活检证实的AL淀粉样变性患者,样本量极小。
- 尚未在ATTR淀粉样变性患者中进行临床评估。
- 作者指出需在更大规模、系统设计的临床研究中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Early detection of cardiac amyloidosis (CA) remains challenging, and a PET tracer capable of directly visualizing amyloid deposits could improve diagnosis. Given the shared β-sheet structure of amyloid deposits in CA and Alzheimer's disease (AD), this study aimed to evaluate the suitability of the AD amyloid tracer [18F]Florbetazine for non-invasive detection of CA via preclinical assessments and preliminary clinical evaluation. METHODS: Specific binding and affinity of [18F]Florbetazine to amyloid light-chain (AL) and transthyretin (ATTR) deposits were assessed via in vitro autoradiography on human myocardial sections. Pharmacokinetics and biodistribution were characterized by dynamic micro-PET/CT imaging in healthy Sprague Dawley (SD) rats. Whole-body PET/CT imaging was performed in two healthy volunteers to estimate normal-organ background, and in a single patient with biopsy-proven AL amyloidosis to preliminarily explore diagnostic feasibility. RESULTS: Autoradiography confirmed specific binding of [18F]Florbetazine to both AL and ATTR deposits with high binding affinities (Kd = 20.85 nM and 54.10 nM, respectively). In rats, [18F]Florbetazine exhibited rapid myocardial and renal uptake followed by efficient clearance from normal tissues. In healthy volunteers, background myocardium and renal activity was minimal by 40 min post-injection. In the AL amyloidosis patient, delayed-phase PET/CT imaging (60-70 min) revealed intense myocardium and renal uptake, correlating with renal biopsy findings. CONCLUSIONS: These integrated preclinical and preliminary clinical evaluation demonstrates that [18F]Florbetazine binds cardiac amyloid with high affinity and displays favorable pharmacokinetics, warranting further investigation in larger, systematically designed clinical studies. TRIAL REGISTRATION: Clinical trial registry NCT06593626 (registered 24 May 2024) and NCT06725706 (registered 5 Dec 2024).
引用
- Li Y, Pan M, Yu H, et al. Preclinical and preliminary clinical evaluation of [18F]Florbetazine for non-invasive PET detection of cardiac amyloidosis. Eur J Nucl Med Mol Imaging. 2026. PMID: 41518400. doi:10.1007/s00259-025-07719-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。